ClinicalTrials.gov¤ËµºÜ¤µ¤ì¤¿Î×¾²»î¸³¤Î³µÍפˤϡ¢¼¡¤Î¤è¤¦¤Êµ½Ò¤¬¸«¤é¤ì¤Þ¤¹¡£ Continued Rexin-G treatment will enable the targeted nanomedicine to catch up with tumor growth, halt disease progression, and reduce tumor burden. ¡ÖRexin-G¤Ë¤è¤ë¼£ÎŤò·Ñ³¤¹¤ë¤³¤È¤Ë¤è¤ê¡¢¤³¤ÎɸŪ²½¤µ¤ì¤¿¥Ê¥Î°åÌôÉʤ¬¼ðáç¤ÎÀ®Ä¹¤ËÄɤ¤¤Ä¤¡¢Éµ¤¤Î¿Ê¹Ô¤ò¤¯¤¤»ß¤á¡¢¼ðáçÉé²Ù¤ò¸º¤é¤¹¤³¤È¤¬¤Ç¤¤ë¤Ç¤·¤ç¤¦¡× ¤â¤Á¤í¤ó¡¢¤³¤ì¤Ï¤Þ¤À¼Â¾Ú¤µ¤ì¤¿»ö¼Â¤Ç¤Ï¤Ê¤¯¡¢³«È¯¼Ô¤Î´üÂԤˤ¹¤®¤Þ¤»¤ó¡£
½é¤Î°äÅÁ»Ò¼£ÎŤȤʤë¥ï¥¯¥Á¥óAdvexin¤¬¡¢ÆÃÄê¤Î°äÅÁ»ÒÊѲ½¡ÊAdvexin͸ú¡Ë¤òͤ¹¤ë ƬðôÉô´â´µ¼Ô¤Ë¤ª¤¤¤Æ¥á¥È¥È¥ì¥¥µ¡¼¥È¤ÈÈæ³Ó¤·¤ÆÍ°Õ¤ÊÁ´À¸Â¸Î¨¤Î²þÁ±¤ò¤â¤¿¤é¤·¤¿ ¤È¤ÎÀè¤ÎÂè3Áê»î¸³¤Î·ë²Ì¤¬AACR¡ÊÊÆ¹ñ´â³Ø²ñ¡Ë Centennial Conference on Translational Cancer Medicine 2008¤ÇÊó¹ð¤µ¤ì¤¿¡£
¡¡¾®»ù¤Î°À¼ðáç¡ÊÆù¼ð¡Ë¤Ç¡¢ÃϸǤáÎÅË¡¤È¤·¤Æ¤Î¼ù¾õºÙ˦¥ï¥¯¥Á¥ó¤Ë¤è¤Ã¤Æ¡¢ À¸Â¸Î¨¤¬²þÁ±¤¹¤ë¤³¤È¤¬ÌÀ¤é¤«¤Ë¤Ê¤Ã¤¿¡£ ·ë²Ì¤ÏClinical Cancer Research»ï8·î1Æü¹æ¤Ë·ÇºÜ¤µ¤ì¤ë¡£